Novartis Ag (NVS) Gross Margin (2009 - 2024)
Novartis Ag recorded quarterly Gross Margin of 77.52% in Q2 2024, up 4.72% quarter-over-quarter from 74.02% in Q4 2023, and up 650.0% year-over-year from 10.34% in Q3 2023.
Novartis Ag's Gross Margin history runs 13 years deep, the most recent figure standing at 77.52% for Q2 2024.
- In Q2 2024, Gross Margin rose 650.0% year-over-year to 77.52%; the TTM figure through Jun 2024 stood at 14280.11% (up 1420910.0% YoY), while the FY2025 annual figure was 78.81%, up 151.0% from the prior year.
- Gross Margin came in at 77.52% for Q2 2024 at Novartis Ag, up from 74.02% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 1543209.88% in Q1 2023 to a low of 0.14% in Q2 2022.
- A 5-year average of 97369.68% and a median of 42.12% in 2022 frame the typical range for Gross Margin.
- On a YoY basis, Gross Margin climbed as much as 154319665 bps in 2023 and fell as far as 712755 bps in 2023.
- Novartis Ag's Gross Margin stood at 7098.76% in 2020, then sank by 100 bps to 0.03% in 2021, then soared by 21621085 bps to 7201.57% in 2022, then slumped by 99 bps to 74.02% in 2023, then advanced by 5 bps to 77.52% in 2024.
- According to Business Quant data, Gross Margin over the past three periods registered 77.52%, 74.02%, and 71.01% for Q2 2024, Q4 2023, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 81.93% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 66.31% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 71.88% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 74.24% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 68.16% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 79.24% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -51.69% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 70.22% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 77.52% |
| Dec 31, 2023 | 74.02% |
| Jun 30, 2023 | 71.01% |
| Mar 31, 2023 | 1,543,209.88% |
| Dec 31, 2022 | 7,201.57% |
| Sep 30, 2022 | 0.42% |
| Jun 30, 2022 | -0.14% |
| Mar 31, 2022 | 13.23% |
| Dec 31, 2021 | 0.03% |
| Sep 30, 2021 | 9.29% |
| Jun 30, 2021 | -0.06% |
| Mar 31, 2021 | 4.98% |
| Dec 31, 2020 | 7,098.76% |
| Sep 30, 2020 | 7.56% |
| Jun 30, 2020 | 72.69% |
| Mar 31, 2020 | 74.06% |
| Mar 31, 2019 | 8.94% |
| Dec 31, 2018 | 385.53% |
| Sep 30, 2018 | 215.29% |
| Jun 30, 2018 | 32.18% |
| Mar 31, 2018 | 7.55% |
| Dec 31, 2017 | 405.94% |
| Sep 30, 2017 | 432.81% |
| Jun 30, 2017 | 4,267.36% |
| Dec 31, 2016 | 63.36% |
| Sep 30, 2016 | 359.36% |
| Jun 30, 2016 | 454.72% |
| Mar 31, 2016 | 352.91% |
| Dec 31, 2015 | 1,496.92% |
| Sep 30, 2015 | 497.24% |
| Mar 31, 2015 | 501.33% |
| Dec 31, 2014 | 106.90% |
| Sep 30, 2014 | 122.58% |
| Mar 31, 2014 | 740.96% |
| Dec 31, 2010 | 5,275,019.37% |
| Jun 30, 2010 | 7,826.90% |
| Dec 31, 2009 | 0.00% |
| Jun 30, 2009 | 75,080.60% |
| Mar 31, 2009 | 75.61% |